CellCarta, Waters Corporation collaborate on companion diagnostics

CellCarta has entered into a strategic partnership with Waters Corporation to develop CDx and next-generation flow cytometry solutions for pharmaceutical and biotechnology companies. Under the framework, the two organisations will initially focus on flow cytometry-based programmes. CellCarta will deploy the assays across its laboratory network, managing Phase I to Phase III clinical trial testing. Credit: Sai Thaw Kyar/Shutterstock.com. CellCarta has entered into a strategic partnership with Waters Corporation to develop companion diagnostic (CDx) and next-generation flow cytometry solutions for pharmaceutical and biotechnology companies. Under the framework, the two organisations will initially focus on flow cytometry-based programmes. Companion Diagnostics Thematic…

Source: Medical Device Network